Guanfacine
- Generic Name
- Guanfacine
- Brand Names
- Intuniv, Tenex
- Drug Type
- Small Molecule
- Chemical Formula
- C9H9Cl2N3O
- CAS Number
- 29110-47-2
- Unique Ingredient Identifier
- 30OMY4G3MK
- Background
Guanfacine, or BS 100-141, is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974.
Guanfacine was granted FDA approval on 27 October 1986.
- Indication
Guanfacine is indicated alone or as an adjunct with stimulants to treat ADHD.
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Gilles de la Tourette's Syndrome, Hypertension, Migraine
Treatment of Supine Hypertension in Autonomic Failure
- Conditions
- Hypertension
- Interventions
- Drug: PlaceboDietary Supplement: L-arginineOther: Head-up tilt.Other: Local heat stress
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-10-13
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 152
- Registration Number
- NCT00223717
- Locations
- 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
Methylphenidate in Children and Adolescents With Pervasive Developmental Disorders
- Conditions
- Pervasive Development DisordersAttention Deficit Disorder With HyperactivityAutistic Disorder
- First Posted Date
- 2001-10-24
- Last Posted Date
- 2009-07-28
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 60
- Registration Number
- NCT00025779
- Locations
- 🇺🇸
Indiana University-Riley Hospital for Children, Indianapolis, Indiana, United States
🇺🇸UCLA Neuropsychiatric Institute, Los Angeles, California, United States
🇺🇸Kennedy Krieger Institute, Baltimore, Maryland, United States
Guanfacine for the Treatment of Post Traumatic Stress Disorder (PTSD)
- Conditions
- Post-Traumatic Stress Disorder
- First Posted Date
- 2001-07-05
- Last Posted Date
- 2009-01-21
- Lead Sponsor
- US Department of Veterans Affairs
- Registration Number
- NCT00018603
- Locations
- 🇺🇸
VA Connecticut Healthcare System, West Haven, Connecticut, United States
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder
- Conditions
- Tourette Syndrome
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 35
- Registration Number
- NCT00004376
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.